What Is Trisomy 2? Causes, Symptoms, and Outlook

Trisomy 2 occurs when cells carry three copies of chromosome 2 instead of the usual two. Full trisomy 2, where every cell in the body has the extra chromosome, is incompatible with life and almost always leads to very early miscarriage, often before a pregnancy is even recognized. What doctors and genetic counselors encounter in clinical practice is nearly always mosaic trisomy 2, a condition in which some cells have three copies of chromosome 2 while others have the normal two. The outcomes depend heavily on which tissues carry the extra chromosome, how many cells are affected, and whether a secondary genetic complication called uniparental disomy is also present.

How Trisomy 2 Happens

The extra chromosome 2 originates from an error in cell division called nondisjunction, where a pair of chromosomes fails to separate properly. This can happen during the formation of an egg or sperm, or it can happen after fertilization when the embryo’s cells are dividing. Research into the parental origin of trisomy 2 has found something distinctive: compared to other trisomies, trisomy 2 has a high frequency of cases where the extra chromosome comes from the father.¹ That is unusual because for most autosomal trisomies, errors in the mother’s egg production account for the majority of cases. The mechanics of why chromosome 2 behaves differently during paternal cell division are still not fully understood, but the pattern is consistent enough that researchers consider it a chromosome-specific feature of nondisjunction.

When the error occurs before fertilization (in the egg or sperm), the resulting embryo starts out with trisomy 2 in every cell. If the embryo survives at all, it typically does so because some cells spontaneously lose the extra chromosome during early development, a process called “trisomy rescue.” This is how mosaicism arises: you end up with a mix of trisomic and normal cells. When the error occurs after fertilization, only a subset of cells inherit the extra chromosome from the start, and the proportion of affected cells depends on how early the error happened.

Confined Placental Mosaicism

In many detected cases, trisomy 2 is confined to the placenta, meaning the placental tissue carries the extra chromosome but the fetus itself has a normal chromosome count. This is called confined placental mosaicism, or CPM. It is the most common scenario when trisomy 2 shows up on prenatal testing, and it is also the scenario that generates the most confusion for expectant parents, because the implications are not straightforward.

Even when the fetus has a normal karyotype, a placenta full of trisomic cells can function poorly. The trophoblast, the outer layer of the placenta responsible for nutrient exchange, may not develop properly when a large proportion of its cells carry three copies of chromosome 2. In one well-documented case, a fetus showed intrauterine growth restriction at 20 weeks; after pregnancy termination, analysis confirmed that the placenta’s fibroblasts carried trisomy 2 while the fetal tissues had a normal chromosome count.² Another case involving growth restriction and low amniotic fluid found that the fetal complications were tied to the high levels of trisomy 2 in the placenta’s trophoblast layer, essentially placental insufficiency rather than a problem with the baby’s own cells.³ Placental abnormalities detected by ultrasound, including unusual thickness or structural irregularities, have also been directly attributed to CPM for trisomy 2.⁴

The practical takeaway is that a genetically normal fetus can still have serious growth problems if its placenta is heavily affected by trisomy 2. This makes close monitoring through ultrasound essential even when follow-up testing suggests the fetus itself is chromosomally normal.

When the Fetus Carries Mosaic Trisomy 2

In rarer cases, the fetus itself has some cells with three copies of chromosome 2. True fetal mosaicism for trisomy 2 tends to exist at low levels. In one detailed case study, the trisomic clone was dominant in the placenta (over 80% of placental cells) but did not exceed about 0.6% in fetal tissues.⁵ This wide gap between placental and fetal involvement is typical and partly explains why the condition can be so hard to predict: a high reading from a placental biopsy may not reflect what is happening in the baby at all.

The clinical features of true fetal mosaic trisomy 2 vary considerably. A literature review cataloged the range of reported abnormalities, which include growth restriction, microcephaly, cleft lip, scoliosis, congenital diaphragmatic hernia, cardiac defects, motor delay, and caudal dysgenesis (underdevelopment of the lower spine).⁶ No single feature is universal, and many babies with low-level mosaicism have only one or two of these findings, or none at all. Specific cases in the literature have documented:

Facial differences and extra fingers: One pregnancy with mosaic trisomy 2, abnormal maternal serum screening, and low amniotic fluid resulted in a baby with facial dysmorphism and preaxial polydactyly (an extra digit on the thumb side of the hand).⁷
Diaphragmatic hernia and heart displacement: In a case where amniocentesis revealed mosaic trisomy 2, ultrasound also identified a single umbilical artery, the heart shifted to the right side of the chest, and a diaphragmatic hernia, all confirmed by fetal MRI.⁸
Short long bones and small head: Two cases analyzed together showed that one fetus had long bones measuring smaller than expected for gestational age, while the other had a small head circumference, short femur, and an abnormal cardiac structure.⁹

Growth restriction is by far the most commonly reported feature, appearing in the majority of published cases whether or not the fetus has other structural abnormalities. It makes sense given that the placenta is usually more heavily affected than the fetus, as described above.

The Uniparental Disomy Complication

When trisomy rescue saves an embryo by discarding the extra chromosome 2, the process is random. Sometimes the cell keeps both copies from one parent and loses the copy from the other, leaving the fetus with two normal chromosomes but both inherited from the same parent. This is called uniparental disomy (UPD) of chromosome 2, and it introduces a second layer of genetic risk.

UPD can cause problems in two ways. First, if a parent happens to carry a single copy of a recessive disease-causing gene variant on chromosome 2, the child who inherits both copies of that parent’s chromosome will have two copies of the variant and may develop the disease. This is exactly what happened in a reported case of a four-year-old girl with maternal UPD of chromosome 2: she ended up with two copies of a variant in the SPR gene, causing sepiapterin reductase deficiency, a treatable form of dystonia. The same UPD also made her homozygous for a variant in ZNF142, associated with a neurodevelopmental disorder. Notably, she showed dramatic improvement in motor skills after being started on levodopa treatment.¹⁰

The second potential concern with UPD is genomic imprinting, where certain genes are only active when inherited from a specific parent. If chromosome 2 carried imprinted genes, having both copies from one parent could silence or over-activate those genes. However, the evidence so far suggests that genes on chromosome 2 are not subject to imprinting.¹⁰ That is actually reassuring news: it means UPD of chromosome 2 does not carry the same predictable syndrome risk as UPD of chromosomes where imprinting is well-established. The main concern remains the unmasking of recessive variants that the carrier parent was unaffected by.

How Trisomy 2 Shows Up on Prenatal Testing

Trisomy 2 is most often discovered during routine prenatal screening rather than because of obvious symptoms. Non-invasive prenatal testing (NIPT), which analyzes fragments of placental DNA circulating in the mother’s blood, can flag trisomy 2. But because NIPT is reading placental DNA, and the placenta is frequently the main site of trisomy 2 mosaicism, the test can produce both false positives and misleading results. One published case demonstrated a false-positive NIPT result for trisomy 2 in a pregnancy that actually involved low-level mosaic trisomy 7 at amniocentesis and had a favorable outcome.¹¹

Chorionic villus sampling (CVS) also tests placental tissue and can pick up the trisomic cells. But just like NIPT, a positive CVS result does not confirm that the fetus itself is affected. Amniocentesis, which samples fluid surrounding the fetus and contains fetal cells, is a more direct way to check whether the baby carries the extra chromosome. Even here, though, there can be discrepancies between cultured and uncultured cells from the same sample.¹² Culturing cells in a lab over time can favor the growth of one cell population over another, meaning the proportions in the dish may not match the proportions in the baby. This is why prenatal genetic counselors often recommend more than one type of testing when trisomy 2 appears, and why interpreting the results requires specialist input.

Detailed ultrasound also plays a central role. Even before genetic testing results are finalized, ultrasound findings like growth restriction, low amniotic fluid, structural heart defects, or diaphragmatic hernia can raise suspicion. When trisomy 2 mosaicism has already been identified, serial ultrasounds become the primary tool for tracking whether the pregnancy is progressing normally or whether complications are developing.

Why Trisomy 2 Is So Hard to Predict

The fundamental challenge with mosaic trisomy 2 is that the same genetic finding can lead to vastly different outcomes. A fetus with the same apparent level of mosaicism on amniocentesis as another fetus may develop normally while the other has serious structural problems. Several factors drive this unpredictability.

The proportion of trisomic cells in any one tissue sample does not reliably reflect the proportion elsewhere. A low-level finding in amniotic fluid cells could coexist with heavy involvement of the placenta, leading to growth restriction from poor placental function, or with involvement of a specific organ like the heart. Testing a single tissue is like checking one room for smoke and concluding the whole building is clear.

The timing of trisomy rescue also matters. If the correction happens very early in embryonic development, very few fetal cells end up trisomic, and the baby is more likely to be unaffected. If it happens later, more cell lineages may carry the extra chromosome. Additionally, whether the rescue leads to UPD adds another variable. In the case series described earlier, the pregnancy with maternal UPD 2 alongside confined placental mosaicism and growth restriction still had a favorable fetal outcome, with the trisomic cell line progressively decreasing over the course of the pregnancy.¹²

This progressive decrease of trisomic cells over time has been documented in more than one case and offers some biological hope: the body may continue selecting against cells with the extra chromosome even after birth.

Outlook for Babies with Mosaic Trisomy 2

Given the rarity of the condition and the wide variability in outcomes, there is no single prognosis for mosaic trisomy 2. Some pregnancies end in termination or stillbirth due to severe structural anomalies or profound growth restriction. Others, particularly when mosaicism is confined to the placenta or present at very low levels in fetal tissue, can result in healthy babies. One case report documented a neonate who was normal in growth and psychomotor development at six months of age after a prenatal diagnosis of mosaic trisomy 2.¹³

For families facing a prenatal diagnosis, the key factors that shape prognosis include the proportion of trisomic cells in fetal versus placental tissue, whether UPD is present and whether it has unmasked any recessive conditions, and the ultrasound findings throughout pregnancy. Growth restriction alone, while concerning, does not inevitably mean the baby will have long-term developmental problems, particularly when the fetal karyotype is otherwise normal or only minimally mosaic. Conversely, structural anomalies like diaphragmatic hernia or significant cardiac defects carry their own surgical and developmental implications regardless of the underlying chromosomal cause.

For children born with confirmed mosaic trisomy 2 who show developmental delays, early intervention programs addressing motor and speech development are standard recommendations. The case of the girl with UPD-related sepiapterin reductase deficiency is a useful reminder that some complications of trisomy 2 are treatable when correctly identified. Her dramatic response to levodopa underscores the value of thorough genetic workup in children with UPD, since the specific recessive conditions unmasked can sometimes be managed medically.

What Happens in the Research Lab

Most of what we know about trisomy 2 in humans comes from case reports and small case series. There are no large cohort studies, and the condition is rare enough that a comprehensive natural history has never been assembled. Animal models offer some additional insight. Research using mice with a Robertsonian translocation involving chromosome 2 found that trisomy of mouse chromosome 2 with two maternally derived copies was the most developmentally successful aneuploid karyotype at an early embryonic stage, while trisomy with two paternally derived copies resulted in more developmental delay and occurred less frequently.¹⁴ The finding is interesting partly because it mirrors the human data showing an unusual contribution of paternal errors to trisomy 2, suggesting there may be something about the biology of this chromosome that makes parental origin particularly relevant to survival.

Mouse chromosomes are not direct equivalents of human chromosomes, so these findings cannot be translated one-to-one. But they do suggest that the parental origin of the extra chromosome and the specific genes involved may influence how well an embryo tolerates trisomy, which aligns with the variability seen in human cases. As genomic sequencing becomes cheaper and more routine in prenatal and postnatal settings, researchers may eventually accumulate enough data to identify which specific genes on chromosome 2 drive the most serious complications when present in three copies. For now, the clinical approach remains case-by-case, guided by what testing and imaging reveal in each individual pregnancy.